NCT05704634View on ClinicalTrials.gov

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 18, 2023

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2028

Conditions
Lung Cancer
Interventions
DRUG

Cemiplimab

Given by Injection under the skin every 2 weeks

DRUG

Kevzara (Sarilumab)

Given by IV (vein) over about 30 minutes every 3 weeks.

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT05704634 - A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. | Biotech Hunter | Biotech Hunter